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Context: The treatment of nocturia is a key challenge due to the multi-factorial patho-
physiology of the symptom and the disparate outcome measures used in research.
Objective: To assess and compare available therapy options for nocturia, in terms of
symptom severity and quality of life.
Evidence acquisition: Medical databases (Embase, Medline, Cochrane Systematic
Reviews, Cochrane Central) were searched with no date restriction. Comparative studies
were included which studied adult men with nocturia as the primary presentation and
lower urinary tract symptoms including nocturia or nocturnal polyuria. Outcomes were
symptom severity, quality of life, and harms.
Evidence synthesis: We identified 44 articles. Antidiuretic therapy using dose titration
was more effective than placebo in relation to nocturnal voiding frequency and duration
of undisturbed sleep; baseline serum sodium is a key selection criterion. Screening for
hyponatremia (< 130 mmol/l) must be undertaken at baseline, after initiation or dose
titration, and during treatment. Medications to treat lower urinary tract dysfunction (a-
1 adrenergic antagonists, 5-a reductase inhibitors, phosphodiesterase type 5inhibitor,
antimuscarinics, beta-3 agonist, and phytotherapy) were generally not significantly
better than placebo in short-term use. Benefits with combination therapies were not
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Conclusions: Issues of trial design make therapy of nocturia a challenging topic. The range of
contributory factors relevant in nocturia makes it desirable to identify predictors of response
to guide therapy. Consistent responses were reported for titrated antidiuretic therapy. For
other therapies, responses were less certain, and potentially of limited clinical benefit.
Patient summary: This review provides an overview of the current drug treatments of
nocturia, which is the need to wake at night to pass urine. The symptom can be caused by
several different medical conditions, and measuring its severity and impact varies in
separate research studies. No single treatment deals with the symptom in all contexts,
and careful assessment is essential to make suitable treatment selection.
# 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Nocturia is defined by the International Continence Society
(ICS) as the complaint that an individual has to wake at night
one or more times to void [1]. It reflects the relationship
between the amount of urine produced while asleep, and the
storage by the bladder of urine received. Nocturia can occur
as part of lower urinary tract dysfunction (LUTD), notably in
overactive bladder syndrome (OAB). Nocturia can also occur
in association with other forms of LUTD, such as bladder
outlet obstruction or chronic pelvic pain syndrome. Nocturia
is a feature of systemic conditions affecting water and salt
balance [2], leading to excessive production of urine at all
times (global polyuria) or primarily at night (nocturnal
polyuria), so that nocturia can be a systemic symptom
[3,4]. For example, cardiovascular, endocrine, and renal
disease can affect water and salt homeostasis [5], leading to
increased rate of urine production.
Summarizing the causative categories for nocturia, the
International Consultation on Male Lower Urinary Tract
symptoms (LUTS) [6] listed:1. Bladder storage problems;2. 24-h (global) polyuria (> 40 ml/kg urine output over a
24-h period);3. Nocturnal polyuria (nocturnal output exceeding 20% of
24-h urine output in younger patients, or 33% of urine
output in people aged over 65 yr [1]);4. Sleep disorders;5. Mixed etiology.
Thus, the treatment of nocturia is potentially complex,
and was identified by the European Association of Urology
Guidelines Panel for Male [7_TD$DIFF]non-neurogenic LUTS as a key
challenge. The aim of the current systematic review of
treatment was to assess and compare available therapy
options for nocturia, in terms of symptom severity and
quality of life. The review focusses on men, in view of the
differing lower urinary tract anatomy and medication
options available compared with women.
2. Evidence acquisition
The objectives were to determine the relative benefits and
harms of treatment options for nocturia, and to perform
subgroup and/or sensitivity analysis.
The Embase, Medline, Cochrane Systematic Reviews, and
Cochrane Central (Cochrane Health Technology Assessment,Database of Abstracts of Reviews of Effects, Health
Economics Evaluations Database) were searched with no
restriction on date of publication (date of final search
September 2016). The search strategy was registered on
PROSPERO on October 21, 2015 (http://dx.doi.org/10.15124/
CRD42015027092). Comparative studies were included
(randomized controlled trials [RCTs], and nonrandomized
comparative studies [both prospective and retrospective,
interventional, or observational]), studying adult men
(male-only or mixed sex populations), with nocturia or
nocturnal polyuria as a primary outcome, categorized within
the following symptom groups:1. Nocturia (ICS definition [7], or as defined by trialist) as
the primary presentation (ie, nocturia as the predomi-
nant bothersome symptom);2. Nocturia as a secondary component of LUTS (ie, LUTS
including nocturia);3. Nocturnal polyuria (ICS definition [7], or alternative
definition if stated by the investigating group).
Interventions included: anticholinergics, mirabegron,
a-blockers, 5-a reductase inhibitors, oral phosphodiester-
ase-5 inhibitors, desmopressin, diuretics, sleep-promoting
agents, and phytotherapy. Comparator controls were:
no treatment, placebo, and alternative experimental
treatment.
The primary outcomes were:- Symptom severity for nocturia (outcome measure defined
as < 2 episodes, or cure [ie, no episodes of nocturia] or
reduction in nocturia episodes, or as defined by trialist);- Quality of life for nocturia.
The secondary outcomes were:- Harms: adverse events of treatment and events leading to
potential harm (eg, hyponatremia, voiding difficulties),
withdrawal, or drop-out rates;- Any other outcomes judged relevant by reviewer.
Two review authors independently screened the titles
and abstracts of identified records, and the full text of
potentially eligible records was evaluated using a stan-
dardized form. Risk of bias was assessed, including: random
sequence generation, allocation concealment, blinding,
incomplete outcome data, selective reporting, and other
sources of bias. A list of potential confounders was
[(Fig._1)TD$FIG]















Fig. 1 – Systematic review flow chart.
DARE = Database of Abstracts of Reviews of Effects; HEED = Health Economic Evaluations Database; HTA = Health Technology Assessment; SR = systemic
reviews.
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pathology, severity, or bother of nocturia.
Studies are summarized in Figure 1.
3. Evidence synthesis
3.1. Conservative management
One study investigated a behavioral modification program
with desmopressin in comparison with desmopressin
monotherapy in patients with nocturnal polyuria and
nocturia ( 2 voids/night; Levels of Evidence [LoE] 1b)
[8]. Nocturnal voids declined by –1.5 with combined
therapy, compared with –1.2 on desmopressin alone (not
significant). Another group randomized obese men with
LUTS already on tamsulosin to receive a basic or a
comprehensive weight reduction program (LoE 2b)
[9]. The improvement in nocturia episodes was similar in
both arms (–0.1  0.9). Both studies showed mild adverse
events only in pharmacotherapy-related arms.
3.2. Antidiuretic therapy
The antidiuretic hormone arginine vasopressin increases
renal water reabsorption and urinary osmolality. Antidi-
uretic therapy using the arginine vasopressin V2 receptoragonist desmopressin, with dose titration to achieve the
best clinical response (as defined by the researchers in each
study; including the dose to achieve either no voids per
night, a decrease in nocturnal urine production of  20%, or
nocturnal diuresis < 0.5 ml/min), was more effective than
placebo in terms of reduced nocturnal voiding frequency
(Table 1) and duration of undisturbed sleep (Table 2).
An RCT evaluated desmopressin (0.1 mg, 0.2 mg, or
0.4 mg, escalated according to response) in adults with 2
voids/night (LoE 1b) [10]. One hundred and twenty-seven
patients (85 men) achieving >20% reduction in nocturnal
diuresis entered a double-blind efficacy phase. More
desmopressin-treated patients showed >50% reduction in
nocturia (33% vs 11%), reduced mean number of nocturnal
voids (39% vs 15%; absolute difference –0.84 voids/night),
and duration of the first sleep.
Adult men (n = 151) with 2 voids/night were studied
for 3 wk, following a dose titration phase (LoE 1b)
[11]. Nocturnal voids decreased from 3.0 to 1.7 on
desmopressin (vs 3.2–2.7 on placebo), with 34% and 3%
experiencing fewer than half the number of nocturnal voids,
respectively. Mean duration of the first sleep period
increased from 2.7 h to 4.5 h (vs 2.5–2.9 h). A fall in serum
sodium level to<130 mmol/l was seen in 4% of patients. In a
small short-term crossover study incorporating a dose-
response titration, desmopressin was associated with a
Table 3 – Adverse effects (AEs) during desmopressin treatment, in







Patients exposed (n) 122 224 184
Total AE, n (%) 62 (50) 107 (48) 93 (51)
Serious AE 3 (3) 1 (<1) 3 (2)
Deaths 0 1 (<1)a NR
AE related to
study medication
37 (39) 60 (27) 52 (28)
Headache 10 (8) 26 (12) 17 (9)
Nausea 5 (4) 10 (4) NR
Hyponatremia 3 (3) 8 (4) 6 (3)
Abdominal pain NR NR 8 (4)
Dry mouth NR NR 5 (3)
Micturition frequency 0 NR NR
Dizziness 6 (5) NR 1 (1)
Fatigue NR NR NR
Peripheral edema NR NR NR
Hypertension 4 (3) NR 3 (2)
Diarrhea NR 9 (4) NR
Insomnia NR NR 3 (2)
Diplopia NR NR 1 (<1)
Depression NR NR 1 (<1)
NR = not reported.
a Unlikely to be study related (exacerbation of chronic lung disease).
Table 1 – Effect of desmopressin (with dose titrated against response) on nocturnal voiding frequency
Desmopressin Placebo Mean difference
Study or subgroup Mean SD Total Mean SD Total Weight (%) IV, fixed, 95% CI
Asplung 1999 –0.8 0.99 17 –0.2 1.1 17 15.4 –0.60 (-1.30, 0.1)]
Fu 2011 –1.5 1.28 39 –0.3 1.41 41 21.9 –1.20 (-1.79, –0.61)
Mattiasson 2002 –1.3 1.25 81 –0.5 1.75 62 28.8 –0.80 (-1.31, –0.29)
Rezakhanina 2011a –1 0 30 –0.2 0 30 Not estimable
Van Kerrebroeck 2007 –1.25 1.35 59 –0.4 1.29 61 34.4 –0.85 (1.32, –0.38)
Wang 2011b –1.5 0 57 –0.8 0 58 Not estimable
Total (95% CI) 283 269 100 –0.87 (–1.15, –0.60)
Heterogeneity: x2 = 1.85, df = 3 (p = 0.60); I2 = 0%
Test for overall effect: Z = 6.21 (p < 0.00001)
CI = confidence interval; df = difference; SD = standard deviation.
a No standard deviation values.
b No standard deviation values.
Table 2 – Effect of desmopressin (with dose titrated against response) on hours of undisturbed sleep
Desmopressin Placebo Mean difference
Study or subgroup Mean SD Total Mean SD Total Weight (%) IV, fixed, 95% CI
Asplung 1999a 102 0 17 18 0 17 Not estimable
Fu 2011 69.6 52.798 39 23.7 50.434 41 50.9 45.90 (23.25, 68.55)
Mattiasson 2002 110.4 102.71 81 24 84.483 62 27.7 86.40 (55.70, 117.10)
Rezakhanina 2011b 120 0 30 30 0 30 Not estimable
Van Kerrebroeck 2007 108 106.5236 59 40 87.055 61 21.5 68.00 (33.13, 102.87)
Wang 2011b 23 0 57 3 0 58 Not estimable
Total (95% CI) 283 269 100 61.85 (45.70, 78.00)
Heterogeneity: x2 = 4.48, df = 2 (p = 0.11); I2 = 55%
Test for overall effect: Z = 7.51 (p < 0.00001)
CI = confidence interval; df = difference; SD = standard deviation.
a No standard deviation values.
b No standard deviation values.
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micturitions at night than for placebo (1.1 vs 1.7,
p < 0.001; mean difference 0.59) [12]. Twenty-four-hour
diuresis was unaffected. Another RCT looked at 60 men
receiving 0.1-mg desmopressin or placebo for 8 wk (LoE 2b)
[13]. Mean number of nocturia episodes reduced from 2.6 to
1.6 (vs placebo 2.5 to 2.3).
Antidiuretic therapy adverse effects are summarized in
Table 3. The key adverse event of hyponatremia (<
125 mmols/l), while rare, means that baseline sodium level
(< 130 mmols/l) was a selection criterion in research
studies, and accordingly review of sodium levels is essential
during treatment. An RCT of 115 men older than 65 yr with
nocturia and nocturnal polyuria compared placebo with
nontitrated 0.1 mg desmopressin (LoE 1b) [14], showing
decreased nocturnal urine output and number of nocturia
episodes (p < 0.01). The authors stated that long-term
desmopressin might induce hyponatremia gradually, but
specific data provided was limited.
Options for formulation and reduced dose level have
been further investigated. A 4-wk placebo-controlled
exploratory study described outcomes with low doses
(10–100 mg) of desmopressin in 757 people (55% men; LoE
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 5 7 – 7 6 9 7611b) [15]. Nocturia severity was around 3 episodes/night,
and 90% of patients had nocturnal polyuria. Increasing
doses of desmopressin were associated with decreasing
numbers of nocturnal voids and voided volume, greater
responder rates, and increased first sleep period duration.
Reductions in serum sodium to <125 mmol/l occurred in
two men taking 100 mg desmopressin. A 3-mo RCT reported
on desmopressin orally disintegrating tablets or placebo in
385 men with 2 nocturnal voids (LoE 1b) [16]. Fifty
micrograms (–0.37) and 75 mg (–0.41) desmopressin
reduced the number of nocturnal voids, and increased
the time to first void by approximately 40 min. Two patients
on 50 mg desmopressin and nine on 75 mg developed a
serum sodium level<130 mmol/l. A separate study in Japan
reported similar findings (LoE 1b) [17].
Intranasal administration was trialed in 20 men with
nocturnal polyuria in a short-term cross-over RCT compar-
ing placebo or 20 mg desmopressin, followed by an open
period with 40 mg desmopressin (LoE1b) [18]. Desmopres-
sin reduced nocturnal urine volume and the percentage of
urine passed at night. However, the reduction in nocturnal
frequency was only significant during unblinded treatment
with 40 mg desmopressin.
3.3. Medications to treat LUTD
3.3.1. Selective a-1 adrenergic antagonists
An 8-wk study assessed tamsulosin (oral controlled
absorption system formulation) in men (aged > 45 yr,
International Prostate Symptom Score [IPSS] > 13, maxi-
mum flow rate 4–12 ml/s, and > 2 nocturnal voids; LoE 1b)
[19]. The mean increase in hours of undisturbed sleep was
60 min for placebo and 82 min for tamsulosin (p = 0.198).
The mean reduction in nocturnal voids was –1.1 for
tamsulosin (–0.7 for placebo, p = 0.099). The mean reduc-
tion in IPSS was 8.0 for tamsulosin (vs 5.6, p = 0.0099). Eight
treatment-emergent adverse events were reported with
tamsulosin, 10 with placebo.
Several studies used a-adrenergic blockade as compara-
tor arms, and these are summarized in Table 4. One study
randomized 31 men with benign prostate enlargement
(BPE) and nocturia 3/night to 2 mg doxazosin for 2 wk
increasing to 4 mg, versus 20 mg intranasal desmopressin
[20]. In the doxazosin group, nocturia reduced from 3.2/
night to 1.2/night, versus 3.4–1.5 for desmopressin.
Improvements in nocturia, quality of life and peak flow
rates were not significantly different, while change in IPSS
was better in the doxazosin group. Another trial random-
ized men to receive either naftopidil 50 mg or tamsulosin
0.2 mg (LoE 2b) [21]. At 2 wk, patients on naftopidil
significantly improved their nocturia score, but at 8 wk the
results were comparable between the two arms.
A post-hoc subgroup analysis of three pooled studies
using silodosin 8 mg in men with LUTS looked at responses to
Question 7 of the IPSS (‘‘How many times did you typically
get up at night to urinate?’’; LoE 1b) [22]. More men treated
with silodosin reported nocturia improvement (53% vs 43%,
p < 0.0001) and fewer patients worsening (9% vs 14%,
p < 0.0001). In men with >2 nocturnal voids at baseline,61% and 49% of patients with silodosin and placebo had
reductions of >1 voids/ night, respectively (p = 0.0003). A
multicenter 12-wk trial randomized men to receive silodosin,
tamsulosin, or placebo and found that only silodosin
significantly reduced nocturia versus placebo (p = 0.013)
and the change from baseline was –0.9, –0.8, and –0.7 for
silodosin, tamsulosin, and placebo, respectively (LoE 1b) [23].
An RCT compared tamsulosin versus TURP for nocturia in
66 men with LUTS suggestive of BPE and no other
predisposing factors for nocturia (LoE 2b) [24]. Both
tamsulosin and TURP improved nocturia, with a greater
response seen with TURP in the number of nocturnal
awakenings and in symptom scores.
The combination of desmopressin and tamsulosin is
superior to tamsulosin alone, since it reduces nocturnal
frequency (–1.96 vs –1.41) and increases the first period of
sleep (77.9 min vs 40.6 min), respectively (LoE 2b) [25]. The
add-on of mirabegron to tamsulosin significantly improved
IPSS Question 7 score from baseline compared with
tamsulosin monotherapy (–0.47 vs –0.16, respectively;
LoE 2b) [26]. Evidence from the CombAT study suggests that
the combination of dutasteride and tamsulosin is more
efficient at reducing nocturia score compared with tamsu-
losin monotherapy (LoE 1b) [27].
Headache is the most frequent adverse event with
tamsulosin therapy (3.2–5.5%). Dry ejaculation is more
common with silodosin than tamsulosin or placebo (14.2%
vs 2.1% vs 1.1%, respectively, p < 0.001).
3.3.2. Antimuscarinics
A post-hoc analysis of two 12-wk RCTs of tolterodine 4-mg
extended release, evaluated 745 men with 2.5 or more
nocturia episodes/night, using a 7-d diary capturing
urgency scores for each void (LoE 1b) [28]. Tolterodine
significantly reduced the weekly values for night-time
severe OAB micturitions. Adverse events showed a higher
incidence of dry mouth for tolterodine (11% vs 4%). Using
bladder diaries in which each void was attributed as ‘‘non-
OAB’’ or OAB, another study randomized tolterodine
extended release 4 mg against placebo (LoE 1b) [29]. Tolter-
odine reduced OAB-related nocturnal micturitions, but not
the total nocturnal micturitions.
A 3-mo RCT of 963 adults with OAB evaluated
fesoterodine flexible dosing for nocturnal urgency ( 2/
night; LoE 1b) [30]. Change in mean number of nocturnal
urgency episodes (1.28 vs 1.07) and nocturnal micturi-
tions (–1.02 vs –0.85) was greater with fesoterodine than
placebo. A separate post-hoc analysis of a 12-wk RCT
studied 555 Asian adults with 2 nocturia, 8 voiding, and
1 urgency urinary incontinence episodes/24 h (LoE 2b)
[31]. Reductions in nocturia were not significantly different
(fesoterodine 4 mg –0.63, 8 mg –0.77, vs placebo –0.56).
When patients with a nocturnal polyuria index >33% were
excluded, the decrease in nocturia was significantly greater
with fesoterodine 8 mg verus placebo. Increases in noctur-
nal voided volume/micturition were greater with fesoter-
odine 4 (+38 ml) and 8 mg (+42 ml) than placebo (+15 ml).
Subgroup analysis of data from an RCT of Japanese OAB
patients, showed solifenacin 10 mg decreased nocturia by
Table 4 – Randomized controlled trials comparing drug therapy against tamsulosin for nocturia
Study description Results Outcome
Comparator Tamsulosin
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Gorgel, 2013, [46] Tamsulosin 0.4 mg +
















12 wk 339 63.5  NA (45–83) 171 –0.5, 0.1 63.5  NA (45–84) 167 –0.5, 0.1 0.0 (–0.02, 0.2) No difference





12 wk 955 65.8  7.7 (50–87) 371 –0.9, NA 66  7.4 (50–81) 376 –0.8 Not estimable Silodosin is superior
to placebo only
Ukimura 2008, [21] Naftopidil 50 mg vs
tamsulosin 0.2 mg
Men 50 yr, BPH,
OAB, nocturia 2,
flow rate <15 ml/s
6–8 wk 59 69.6  6.8 (NA) 25 –3.8, 0.2 68.8  8.2 (NA) 23 –3.1, 0.1 –0.7
(–0.79, –0.61)
Early improvement
(2 wk) in naftopidil
arm but results are
comparable at 8 wk
Ichihara 2014 [26] Mirabegron +
tamsulosin 0.2 mg vs
tamsulosin 0.2 mg






Ahmed 2015, [25] Desmopressin +
tamsulosin vs
tamsulosin 0.4 mg
Men 50 yr, BPH,
LUTS, nocturia 2






Data modified for the purposes of the table.
BMI = body mass index; BPH = benign prostatic hyperplasia; CI = confidence interval; IPSS = International Prostate Symptom Score; IV = independent variable; LUTS = lower urinary tract symptoms; NA = not available;
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increased night-time volume voided per micturition by
30 ml and 41 ml (p = 0.0033 and p < 0.0001, respectively).
Propiverine was not superior to placebo in reducing
nocturia frequency (p = 0.471; LoE 1b) [33]. Similar results
were seen from another placebo controlled trial which
compared propiverine versus solifenacin (LoE 1b) [34]. Only
solifenacin 10 mg resulted in statistically significant reduc-
tions in the number of nocturia episodes versus placebo
(p = 0.021).
Adverse events attributable to antimuscarinic medica-
tions (eg, dry mucous membranes, constipation, gastro-
esophageal reflux) have been extensively reported in OAB,
and there is no suggestion that they differ in a population of
patients with nocturia.
3.3.3. Beta-3 agonist
Data from a phase 2 dose-ranging study of mirabegron in a
mixed population with OAB, showed that mirabegron
50 mg reduced nocturia episodes by 0.6 from baseline (vs
0.22 on placebo, p < 0.05; LoE 1b) [35]. Adverse events
attributable to mirabegron (eg, hypertension) have been
reported in OAB studies.
3.3.4. 5-a reductase inhibitors (alone or in combination)
Pooled data from dutasteride phase 3 studies looking at
results of IPSS Question 7 has been reported for
4321 patients (LoE 1b) [36]. Improvements in overall
nocturia parameters were superior with dutasteride versus
placebo from 12 mo onwards. The largest treatment group
differences were seen in patients with a baseline nocturia
score of 2 or 3.
A post-hoc subgroup analysis of self-reported nocturia in
the Medical Therapy of Prostatic Symptoms trial of men
with LUTS (LoE 1b) [37] found mean nocturia was reduced
by –0.35, –0.40, –0.54, and –0.58 in the placebo, finasteride,
doxazosin, and combination groups at 1 yr. Reductions with
doxazosin and combination therapy, but not finasteride,
were greater than with placebo at 1 yr and 4 yr.
A secondary analysis of the Veterans Affairs Cooperative
Study Program Trial reported on 1078 men (LoE 2b)
[38]. From a baseline mean of 2.5, nocturia decreased to
1.8, 2.1, 2.0, and 2.1 in the terazosin, finasteride, combina-
tion, and placebo groups, respectively. Of men with 2
episodes of nocturia, 50% reduction was seen in 39%, 25%,
32%, and 22%.
Adverse events attributable to 5-a reductase inhibitors
(eg, reduced ejaculate volume and effects on prostate-
specific antigen) have been extensively reported in male
voiding LUTS patients, and there is no suggestion that they
differ in a population of patients with nocturia.
3.3.5. PDE5 inhibitor
Separately, individual studies using tadalafil did not show
significant improvement in nocturia. An analysis of four
registrational RCTs of tadalafil for LUTS evaluated pooled
responses to IPSS Question 7 (LoE 1b) [39]. Overall severity
of nocturia was 2.3  1.2, and the mean treatment change
was –0.4 with placebo and –0.5 with tadalafil. Improvednocturnal frequency was seen in 47.5% on tadalafil (41.3% with
placebo), and worse in 11.5% (vs 13.9%), which was not
considered clinically meaningful.
Adverse events attributable to PDE5 inhibitors have been
extensively reported in erectile dysfunction patients, and




Administration of a diuretic in the afternoon has been
proposed to reduce salt and water load in the body prior to
bedtime. A double blind RCT compared diuretic therapy
(azosemide 60 mg) against diazepam (5 mg) in 51 patients
(47 men) with nocturia3/night and no daytime urological
problems (LoE 2b) [40]. For people with a higher atrial
natriuretic peptide at baseline, daytime diuretic decreased
the nocturnal frequency. Diazepam decreased nocturia in
22 out of 29 patients.
The efficacy of 1 mg bumetanide was evaluated in an RCT
of 28 patients (15 men) in general practice (LoE 2b)
[41]. During the placebo period the weekly number of
nocturia episodes was 13.8 and during bumetanide
treatment the number was reduced by 3.8. Ten men with
BPE did not improve with bumetanide.
An RCT of 49 men with nocturnal polyuria evaluated
furosemide 40 mg given 6 h before sleep (LoE 1b) [42],
yielding a decrease of 0.5 voids/night, versus 0 for placebo.
Another study reported a strategy of furosemide and
desmopressin for nocturia ( 2 voids/night) in the elderly
(LoE 1b) [43]. Eighty-two patients (58 men) were random-
ized to receive furosemide (20 mg, 6 h before bedtime) and
the individual’s optimal dose of desmopressin (at bedtime)
or placebo for 3 wk. Reduced nocturnal voids (3.5 vs 2.0,
p < 0.01) and urine volume (920 ml vs 584 ml, p < 0.01)
were observed with active treatment.
Some diuretics work by causing natriuresis, and hence
may be contraindicated in patients with hyponatremia, or
at risk of acquiring it.
3.4.2. Nonsteroidal anti-inflammatory drugs
Diclofenac taken in the late evening was evaluated in
nocturnal polyuria [44]. Twenty-six patients (20 men, mean
age 72 yr) received 2 wk of placebo or active medication,
crossing-over following a 1-wk rest period. Nocturia
decreased from 2.7 to 2.3 (p < 0.004). An RCT of celecoxib
100 mg versus placebo was undertaken in 80 men with BPE
and 2 nocturia/night (LoE 1b) [45]. In the celecoxib group,
mean nocturnal frequency decreased from 5.2 to 2.5 com-
pared with 5.3 to 5.1. No significant side effects were
reported in either study.
Tamsulosin (0.4 mg) alone or combined with meloxicam
(15 mg), have been compared in 400 men with LUTS and
nocturia (LoE 1b) [46]. Total IPSS, IPSS-Quality of Life,
nocturia, and sleep quality score were significantly lower
with combination therapy. A RCT randomized 40 men to
loxoprofen, a-blocker, and 5-a-reductase inhibitors
(vs a-blocker and 5-a-reductase inhibitors; LoE 2b)
Table 5 – Effect on nocturnal voiding frequency of drug therapies compared against placebo



















































60 –1.1, NA 67.6  7.6,
(NA)









>6 mo, IPSS 13,
max flow rate
4–15 ml/s




165 –0.5, 0.1 63.7  NA,
(46–89)











>6 mo, IPSS 13,
max flow rate
4–15 ml/s




171 –0.5, 0.1 63.7  NA,
(46–89)
















321 –0.42, 1.5 61.5  12.2,
(NA)


















309 –0.46, 1.4 61.5  12.2,
(NA)


















31 –0.83, 0.1 67.4  NA,
(47–85)















348 –0.43, 1.2 60.8  13.3,
(20–89)
361 –0.3, 0.9 –0.13,
(–0.29, 0.03)
Propiverine is not
superior to placebo in
controlling nocturnal
frequency










344 –0.43, 1.2 60.8  13.3,
(20–89)
361 –0.3, 0.9 –0.13,
(–0.29, 0.03)
Solifenacin 5 mg is
not superior to
placebo










334 –0.46, 0.9 60.8  13.3,
(20–89)
3.61 –0.3, 0.9 –0.16,
(–0.29, –0.03)
Solifenacin 5 mg is
superior to placebo










284 –0.29, 0.6 58.7  14.1,
(21–93)





















































145 –0.52, 1.3 57.1  12.9,
(NA)
144 –0.44, 1.1 –0.08,
(–0.36, 0.2)
Mirabegron 25 mg is
not superior to
placebo














142 –0.6, 1.3 57.1  12.9,
(NA)
144 –0.44, 1.1 –0.16,
(–0.44, 0.12)
Mirabegron 50 mg is
superior to placebo














141 –0.42, 1.3 57.1  12.9,
(NA)
144 –0.44, 1.1 0.02,
(–0.26, 0.30)
Mirabegron 100 mg is
not superior to
placebo














147 –0.59, 1.3 57.1  12.9,
(NA)
144 –0.44, 1.1 –0.15,
(–0.43, 0.13)
Mirabegron 200 mg is
not superior to
placebo














72 –0.59, 1.2 57.1  12.9,
(NA)
144 –0.44, 1.1 –0.15,
(–0.49, 0.19)
Tolterodine ER 4 mg is
not superior to
placebo









19 –0.3, 0.9 72.2  NA,
(60–81)














23 –0.5, na 69  NA,
(NA)
20 0, NA Not estimable Furosemide improves
nocturnal frequency
in NP patients












































Adla 2006, [44] Diclofenac
50 mg





26 –0.5, 0.23 72  NA,
(52–90)





















Cannon 1999, [18] Desmopressin
20 mg





18 –0.3, 0.45 70.5  NA,
(52–80)




Cannon 1999, [18] Desmopressin
40 mg





18 –0.7, 0.39 70.5  NA,
(52–80)





BPH = benign prostatic hyperplasia; CI = confidence interval; ER = extended release; IPSS = International Prostate Symptom Score; IV = independent variable; LUTS = lower urinary tract symptoms; NA = not available;
NP = nocturnal polyuria; OAB = overactive bladder; SD = standard deviation.


































Table 6 – European Association of Urology Guidelines Panel for Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS)
recommendations on medication treatment of nocturia in men
LE GR
Treatment should aim to address underlying causative factors, which may be behavioral, systemic condition(s), sleep disorders, lower urinary
tract dysfunction, or a combination of factors
4 Aa
Lifestyle changes to reduce nocturnal urine volume and episodes of nocturia, and improve sleep quality should be discussed with the patient 3 Aa
Desmopressin may be prescribed to decrease nocturia in men under the age of 65 yr. Screening for hyponatremia must be undertaken at
baseline, during dose titration and during treatment
1a A
a-1 adrenergic antagonists may be offered to men with nocturia associated with lower urinary tract symptoms 1b B
Antimuscarinic drugs may be offered to men with nocturia associated with overactive bladder 1b B
5a-Reductase inhibitors may be offered to men with nocturia who have moderate-to-severe LUTS and an enlarged prostate (> 40 ml) 1b C
PDE5 inhibitors should not be offered for the treatment of nocturia 1b B
A trial of timed diuretic therapy may be offered to men with nocturia due to nocturnal polyuria. Screening for hyponatremia should be
undertaken at baseline and during treatment
1b C
Agents to promote sleep may be used to aid return to sleep in men with nocturia 2 C
GR = grade; LE = level of evidence; PDE5 = phosphodiesterase type 5.
a Upgraded based on panel consensus.
[(Fig._2)TD$FIG]
Fig. 2 – Risk of bias.
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nonsteroidal anti-inflammatory drugs (NSAID) experienced
a greater reduction in nocturia (–1.5  0.9 vs –1.1  0.9,
p = 0.034), but with a higher incidence of gastrointestinal side
effects. Gastric discomfort with loxoprofen was seen in 12.5%,
as compared with 2.6% of the control group.
3.4.3. Phytotherapy
An 8-wk placebo-controlled RCT looked at SagaPro (Saga-
Medica, Reykjavik, Iceland), a product derived from Angelica
archangelica leaf, in 69 men with 2 nocturnal voids (LoE
1b) [48]. The study found no significant difference between
the treatment groups, except on post-hoc subgroup
analysis. In a crossover trial of furosemide and gosha-
jinki-gan, 36 patients were reported to have improved
symptom score, quality of life, nocturnal frequency, and
hours of undisturbed sleep with both medications (LoE 2b)
[49].
3.4.4. Agents to promote sleep
A crossover RCT of 20 men with bladder outflow obstruction
and nocturia (mean 3.1/night) compared 2 mg melatonin
with placebo (LoE 1b) [50]. Melatonin and placebo caused a
decrease in nocturia of 0.32 and 0.05 episodes/night
(p = 0.07). Nocturia responder rates (a mean reduction of
at least –0.5 episodes/night) were higher with activemedication (p = 0.04). Daytime urinary frequency and IPSS
were minimally altered.
3.4.5. Summary of medical therapy of nocturia in men
A summary of the effect of medical therapy, excluding
antidiuretic, on nocturia is given in Table 5. Risk of bias
summary for all treatments is given in Figure 2, and a table
for individual studies is given in Supplementary data.
Recommendations from the European Association of
Urology Guidelines panel for Nonneurogenic Male LUTS
are given in Table 6.
4. Conclusions
A detailed review of principal medical therapies of nocturia
has been presented. It assumes that conservative measures
are addressed as part of the care package. The nature of the
reports included reflects the importance of several influ-
ences; the use of subjective or objective markers as primary
outcomes, the range of severity included (twice per night
being a commonly applied threshold), and the importance
of subjective ‘‘bother.’’ The differences apparent in pub-
lished literature in regards to populations, definitions, study
design, outcome measures, and treatment durations repre-
sent a substantial limitation for the evidence base of
nocturia therapy. In nocturia, some trials report an
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but which might actually be comparatively small, making
the clinical relevance potentially marginal. In addition, the
studies described generally take a pragmatic approach of
measuring all nocturnal voids, which is somewhat different
from the ICS definition, which focusses on patients who
‘‘wake at night to void.’’ Very little published evidence is
available to signify what implications this could have for
interpretation of results.
The review identified that antidiuretic therapy using
clinician-directed dose titration was more effective than
placebo in terms of reduced nocturnal voiding frequency and
duration of undisturbed sleep. Nocturia severity improve-
ment contributes to overall improvements in health-related
quality of life [51]. The potential to worsen severity of the
abnormality means that hyponatremia is a contraindication
to antidiuretic therapy. Screening for hyponatremia must be
undertaken at baseline, after initiation or dose titration and
during treatment. The cumulative risk of hyponatremia over
time is not clear, although evidence suggests that sodium
imbalance may happen at any time during treatment. Three
out of nine desmopressin studies included in this systematic
review [10–12] undertook dose titration with the active
treatment; this study design was to assign patients to the
dose with treatment response and also for safety consider-
ations. Clearly, a response selection phase will increase the
likelihood of a positive outcome in the RCT and the
associated effect sizes, since nonresponders will be excluded
before the full trial. Nonetheless, dose titration is a process
which can be undertaken in clinical practice in order to tailor
therapy to individual patients, both in terms of efficacy and
safety. Such a process adds to the burden on patients and
healthcare providers in increasing the number of clinical
contacts required.
Medications to treat LUTD in men (a-1 adrenergic
antagonists, 5-a reductase inhibitors, PDE-5 inhibitor, phy-
totherapy) were not significantly better than placebo in short-
term use. Data on OAB medications (antimuscarinics, beta-3
agonist) generally had a female-predominant population, and
were also not significantly better than placebo in short-term
use. It is an assumption that this would also apply in male-
only populations, but no studies specifically addressing the
impact of OAB medications on nocturia in men were
identified. Subcategorizing the ‘‘OAB-related’’ nocturia epi-
sodes appeared to yield benefit for antimuscarinic therapy in
one trial. Potential benefit was seen in long-term use in some
studies using a-1 adrenergic antagonists and 5-a reductase
inhibitors. Differences between therapies emerged in studies
where a-1 adrenergic antagonist was the comparator.
Benefits with combination therapies were not consistently
observed. Other medications (diuretics, agents to promote
sleep, NSAIDs), were sometimes reported as being associated
with response or quality of life improvement. Nonetheless,
additional research is needed to corroborate initial findings,
particularly for therapies like NSAIDs, where the mechanism
of action is uncertain.
The symptom of nocturia is an important one, since there
may a significant medical cause, potentially an opportunity to
screen for undiagnosed or suboptimally-managed disease,perhaps reduced incidence of severe complication, and
potential economic benefits. Accordingly, clearly-relevant
causes of nocturia that can be treated by mechanism-specific
approaches, such as poorly controlled diabetes mellitus,
congestive heart failure, or sleep apnoea, require direct
intervention as the principal therapeutic priority. Since
nocturia is a symptom rather than a disease, causative
categories have been proposed [6], and the diversity of the
affected population is manifest. The range of potentially
relevant contributors may well affect therapy outcome.
Despite this, research populations often include diverse
individuals, and may not undertake the full extent of
evaluation needed to categorize factors likely to affect therapy
response. However, the testing may limit the ability to deliver
a trial, and may be unfeasible in routine clinical practice. The
likelihood of developing a therapy that can be generalized
appears remote, so nocturia therapy choice needs to consider
the specific situation of individual patients. Accordingly, the
studies need to be considered for analysis of responders, as
well as the overall population response, since this may help
develop improved approaches to clinical assessment in the
future. Responder analysis is particularly interesting in
studies reporting modest reductions in nocturia, which might
be reported as statistically significant, but which are hard to
perceive as clinically significant. In such a setting, responder
analysis may help identify whether a subgroup did get a larger
(clinically more useful) reduction in nocturia severity;
predictors of response to enable targeting of therapy to
individuals more likely to benefit would be a helpful advance.
Objective markers are scientifically preferable, but some
studies have used patient perception (such as the IPSS
Question 7), which is not uniformly consistent with
objective markers. Furthermore, reported effect sizes are
sometimes greater than perceived in clinical practice, so
findings of many studies merit independent corroboration
and follow up with real-life studies. Effect size is also likely
to be affected by baseline severity, and this should be
considered in the evaluation of trial outcomes. Finally, there
is very little information on long-term outcomes of drug
therapy for nocturia.
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